ECE2023 Poster Presentations Late-Breaking (40 abstracts)
Genetic profile of bone metabolism and immunity modulators in bone metastasis in castration-resistant prostate cancer
Matthew Janeiro 1 , Andreia Matos 1,2,3,4 , Rui Medeiros 5,6,7,8 , Manuel Bicho 1,4 & Ricardo Ribeiro 2,9
1Laboratório de Genética, Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; 2Tumour & Microenvironment Interactions Group, i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; 3Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Porto, Portugal; 4Instituto de Investigação Bento da Rocha Cabral, Lisbon, Portugal; 5Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal; 6Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal. Virology Service, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal; 7Biomedical Research Center (CEBIMED), Faculty of Health Sciences of the Fernando Pessoa University, Porto, Portugal; 8Research Department, Portuguese League Against Cancer - Regional Nucleus of the North (Liga Portuguesa Contra o Cancro - Núcleo Regional do Norte), Porto, Portugal; 9Department of Pathology, Centro Hospitalar Universitário Santo António, Porto, Portugal
Introduction: Prostate cancer is a neoplasm with high incidence and prevalence in the elderly population in western countries. Androgen deprivation therapy (ADT) has been used in locally advanced or metastatic disease, although most relapse, becoming hormone resistant, which is a poor prognostic event.
Objectives: The aim of this study was to evaluate the association of genetic polymorphisms NOS2, GPRC6A, VKORC1, ARGI and ARGII in prostate cancer, particularly to assess their predictive value for the development of hormone resistance in individuals under ADT therapy.
Methods: 107 patients with PCa, aged 67-76 years, were included in this study. Most had PCa at an advanced stage, with 65.5% of patients having metastases at diagnosis. DNA was extracted from whole blood. NOS2, GPRC6A, VKORC1, ARGI and ARGII polymorphisms were detected using real-time PCR with Taqman probes and PCR-RFLP.
Results: Carriers of the NOS2 GG genotype were at higher risk for stage T3-T4. In the case of ARGI in the recessive model, that is, for the CC genotype, there is a 2.6 times greater risk for the existence of a PSA level greater than 20 ng/ml according to the univariate and multivariate analysis.
Conclusions: The ARGII GG genotype in the recessive model was related to early diagnosis of the disease. NOS2 and ARGI polymorphisms are associated with aggressive traits, while the ARGII variant affects earlier onset of prostate cancer.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more